Cabenuva FDA approval : ViiV Healthcare has secured approval from the US Food and Drug Administration (FDA) for its long-acting regimen Cabenuva for the treatment of HIV-1 infection in adult patients. According to ViiV Healthcare, Cabenuva is being given as a co-pack with a couple of injectable medicines that include the company’s integrase strand transfer […]
In the latest pharma industry news, ViiV Healthcare has bagged Juluca FDA approval for the maintenance treatment of virologically suppressed HIV-1 infection.
ViiV Healthcare, a joint venture between GlaxoSmithKline (GSK), Pfizer, and Shionogi, has received approval from the U.S. Food and Drug Administration (FDA) for its two-drug regimen, Juluca, for the maintenance treatment of adults with virologically suppressed human immunodeficiency virus type 1 (HIV-1). This groundbreaking treatment, composed of dolutegravir 50mg and rilpivirine 25mg, is the first […]